ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenicss product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ThromboGenics NV, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ThromboGenics Forms Joint Venture with VIB 10
Licensing Agreements 11
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
Equity Offering 15
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV - Key Competitors 18
ThromboGenics NV - Key Employees 19
ThromboGenics NV - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Mar 15, 2018: ThromboGenics Business Update - FY 2017 21
Sep 07, 2017: ThromboGenics Business Update - H1 2017 26
Mar 16, 2017: ThromboGenics Business Update - FY 2016 30
Corporate Communications 34
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 34
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 35
Product News 36
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 36
Other Significant Developments 37
Oct 20, 2017: ThromboGenics Business Update - Q3 2017 37
May 11, 2017: ThromboGenics Business Update Q1 2017 40
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List Of Tables

List of Tables
ThromboGenics NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ThromboGenics NV, Deals By Therapy Area, 2012 to YTD 2018 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ThromboGenics Forms Joint Venture with VIB 10
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV, Key Competitors 18
ThromboGenics NV, Key Employees 19
ThromboGenics NV, Other Locations 20
ThromboGenics NV, Subsidiaries 20

List Of Figures

List of Figures
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ThromboGenics NV (THR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in

USD 250 View Report

ThromboGenics NV Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

ThromboGenics NV Company Profile is a detailed strategic and analytical report on ThromboGenics NV. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Oxurion NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is

USD 250 View Report

ThromboGenics NV (THR) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available